1.	Phase II/III Randomized Study of First-Line Hormonal Therapy With Exemestane Versus Tamoxifen in Postmenopausal Women With Locally Recurrent or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: EORTC-10951, PHARMACIA-EORTC-10951, NCT00002777
2.	Phase III Randomized Study of Exemestane Versus Tamoxifen in Postmenopausal Women With Primary Breast Cancer Who Have Already Received 2-3 Years of Adjuvant Tamoxifen After Potentially Curable Surgery Phase: Phase III Type: Treatment Status: Closed Age: Postmenopausal Sponsor: Protocol IDs: ICCG-96OEXE031-C1396-BIG9702, EORTC-10967, FRE-FNCLCC-PACS02/96OEXE031, EU-20013, EU-99002, ICCG-BIG-97/02, NCT00003418
3.	Phase III Randomized Study of Exemestane in Postmenopausal Women With Resected Stage I, II, or IIIA Breast Cancer Who Have Completed Five Years of Tamoxifen Phase: Phase III Type: Treatment Status: Closed Age: Postmenopausal Sponsor: NCI Protocol IDs: NSABP-B-33, ECOG-NSABP-B-33, NCT00016432
4.	Phase III Randomized Study of Adjuvant Exemestane Versus Adjuvant Tamoxifen in Postmenopausal Women With Early Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: Any age Sponsor: Other Protocol IDs: CRC-TU-TEAM, EU-20149, ISRCTN75225940, NCT00032136
5.	Phase III Randomized Adjuvant Study of Exemestane Versus Anastrozole in Postmenopausal Women With Receptor-Positive Primary Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: Postmenopausal Sponsor: NCI, Other Protocol IDs: CAN-NCIC-MA27 (COMPANION), NCCTG-MA27, CALGB-CAN-NCIC-MA27, ECOG-CAN-NCIC-MA27, SWOG-CAN-NCIC-MA27, NCIC-MA.27, NCT00066573, IBCSG-30-04, EUDRACT-2005-001893-28, MA27
6.	Phase III Randomized Study of Ovarian-Function Suppression and Tamoxifen or Exemestane With Versus Without Adjuvant Chemotherapy in Premenopausal Women With Endocrine-Responsive Resected Breast Cancer Phase: Phase III Type: Treatment Status: Completed Age: Premenopausal Sponsor: NCI Protocol IDs: IBCSG-26-02, BIG-4-02, NABCI-IBCSG-26-02, EU-20401, NCT00066807, EUDRACT-2005-002626-59
7.	The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: 9238IL/0048, EFECT, NCT00065325
8.	Randomized Phase III Study of Exemestane (Aromasin) for 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed by Exemestane Phase: Phase III Type: Treatment Status: Closed Age: 50 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 971-ONC-0028-081, A5991026, NCT00036270
9.	Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 30 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 96-OEXE-031, A5991012, NCT00038467
10.	Phase III Randomized Study of Adjuvant Exemestane Versus Anastrozole in Postmenopausal Women With Hormone Receptor-Positive Primary Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 45 and over Sponsor: NCI Protocol IDs: CAN-NCIC-MA27 (NON-COMPANION), NCIC-MA27 (NON-COMPANION), IBCSG-30-04, NCT00438529, MA27
11.	Phase II Study of Exemestane (an Aromatase Inhibitor) for Postmenopausal Women with Advanced Breast Cancer Refractory to Tamoxifen and Megestrol (Summary Last Modified 11/95) Phase: Phase II Type: Treatment Status: Closed Age: 25 to 90 Sponsor: Other Protocol IDs: YALE-HIC-7480, NCI-V95-0725
12.	Phase II Study of Exemestane (an Aromatase Inhibitor) for Postmenopausal Women with Metastatic Breast Cancer Refractory to Tamoxifen (Summary Last Modified 10/95) Phase: Phase II Type: Treatment Status: Closed Age: postmenopausal Sponsor: Protocol IDs: YALE-HIC-7437, NCI-V95-0726
13.	Phase II Randomized Study of Exemestane and Raloxifene in Postmenopausal Women With a History of Stage 0 (Ductal Carcinoma in Situ), I, II, or III Breast Cancer Who Have No Clinical Evidence of Disease Phase: Phase II Type: Prevention, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-99017, NCI-G99-1662, NCT00004247
14.	Phase II Pilot Study of cDNA Microarray as a Measure of Tumor Response to Neoadjuvant Docetaxel and Capecitabine Followed By Surgery and Adjuvant Doxorubicin and Cyclophosphamide in Patients With Stage II or III Breast Cancer Phase: Phase II Type: Diagnostic, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-00-C-0149, NCT00020241
15.	Phase II Study of Exemestane and Goserelin in Premenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: NYU-0004, P-UPJOHN-NYU-0004, NCI-G00-1906, NCT00010010
16.	Phase II Randomized Study of Exemestane With or Without Bicalutamide as Second-Line Therapy After Failure of Androgen Suppression in Patients With Stage IV Adenocarcinoma of the Prostate Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: SWS-SAKK-09/01, EU-20139, NCT00031889
17.	Phase II Study of Trastuzumab (Herceptin) and Exemestane in Postmenopausal Women With Metastatic or Locally Advanced Hormone-Responsive, HER2/neu Positive Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: NU-01B4, PHARMACIA-NU-01B4, NCT00057993
18.	Phase II Randomized Study of Sorafenib Tosylate in Combination With Letrozole, Anastrozole, or Exemestane in Postmenopausal Women With Estrogen Receptor- and/or Progesterone Receptor-Positive Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 to 44 (if menopausal) or 45 and over Sponsor: NCI Protocol IDs: MAYO-RC0731, RC0731, NCT00573755
19.	Randomized Study of Exemestane for the Reduction of Breast Density in Postmenopausal Women at Increased Risk for Breast Cancer Phase: No phase specified Type: Prevention Status: Closed Age: Postmenopausal Sponsor: Other Protocol IDs: CAN-NCIC-MAP2, PFIZER-971-ONC-0028-088, NCT00066586, MAP2
20.	Study of Changes in Breast Density and Plasma Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N063I, N063I, NCT00516698